ZIA CP010182 10793 (ZIA) | |||
---|---|---|---|
Title | Gastric Cancer Precursor Lesions (GCPL) study | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Camargo, Constanza | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $434,548 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Stomach (100.0%) | ||
Research Type | |||
Cancer Progression & Metastasis Endogenous Factors in the Origin and Cause of Cancer |
|||
Abstract | |||
The burden of gastric adenocarcinoma is unevenly distributed, with several Asian and Latin American countries having particularly high incidence rates. Although chronic infection with Helicobacter pylori is the primary cause of this cancer, environmental and host cofactors modify the course of infection and determine its ultimate outcome as cancer vs. no cancer. Due to the lack of adequate screening strategies and consequent late diagnosis, trends in mortality are similar to incidence, making this neoplasia the third leading cause of cancer death worldwide. It may be expected that the absolute number of gastric cancer cases will remain stable or even increase in future years due to population growth and aging. H. pylori-related gastric carcinogenesis is a multi-step process and mucosal lesions of intestinal metaplasia (IM) and dysplasia confer increased risk of progression. Therefore, case-control studies of these premalignant lesions may provide insights into cancer etiology without the biases inherent in studies of invasive cancer. In addition, biomarkers to identify high-risk individuals are needed for early detection and curative treatment. Accordingly, we propose a 2-year endoscopy-based cross-sectional study of ~10,000 individuals in Chile to identify 600 subjects with advanced preneoplastic lesions (i.e., severe IM and dysplasia) for informative comparisons with 600 controls with non-atrophic gastritis. As an additional case group, 300 individuals with gastric cancer will be recruited. The individuals with advanced IM (n~500) will be recalled at 3 years for repeat endoscopy and biospecimen collection. |